Neurol. praxi. 2022;23(6):477-482 | DOI: 10.36290/neu.2022.050
Long-term efficacy and safety of ofatumumab in the treatment of multiple sclerosis
- Neurologická klinika LF UK a FN Plzeň
The treatment of multiple sclerosis (MS) has gone through significant progress in last couple of years. Although the presence of oligoclonal bands in the liquor is one of the keys for the diagnosis of MS, the function of B lymphocytes in the pathophysiology of this disease has been long time underestimated. Only the invention of drugs that cause B-lymphocyte depletion has demonstrated their ability to suppress disease activity of this diseases. We currently have another drug from this group called ofatumumab. This is the first fully human monoclonal antibody available for the treatment of relapsing-remitting forms of MS. The aim of this article is to present the most recently published safety and efficacy data on ofatumumab.
Keywords: ofatumumab, multiple sclerosis, treatment, monoclonal antibody, B lymphocytes, long‑term efficacy, long‑term safety.
Received: August 9, 2022; Revised: August 9, 2022; Accepted: August 19, 2022; Prepublished online: August 19, 2022; Published: December 2, 2022 Show citation
References
- Hauser SL, Bar‑Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546-557. doi: 10.1056/ NEJMoa1917246.
Go to original source... 
Go to PubMed... - Hauser SL, Fox E, Aungst A, et al. Long-term Efficacy of Ofatumumab in Patients with Relapsing Multiple Sclerosis. AAN 2022; Poster number: P5.004. Go to original source...
- Hauser SL, Cross AH, Winthrop K, et al. Long-term Safety of Ofatumumab in Patients with Relapsing Multiple Sclerosis. AAN 2022; Oral presentation: S14.004. Go to original source...
- He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. Go to original source... Go to PubMed...
- Kubala Havrdová E, et al. Klinický doporučený postup pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica a onemocnění jejího širšího spektra. 2020. Available from: https://www.czechneuro.cz/content/uploads/2020/04/rs_odborna-2.0_final_pub_web-2.pdf.
- Roach CA, Cross AH. Anti‑CD20 B cell treatment for relapsing multiple sclerosis. Front Neurol. 2020;11:595547. Go to original source... Go to PubMed...
- Souhrn údajů o přípravku Kesimpta. [Internet]. Available from: https:/ / www.ema.europa.eu/ en/ documents/ product‑information/ kesimpta‑epar‑productinformation_cs.pdf.
- Spelman T, Magyari M, Piehl F, et. al, Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing‑Remitting Multiple Sclerosis. JAMA Neurol. 2021;78(10):1197-1204. Go to original source... Go to PubMed...
- Teeling JL, Mackus WJM, Wiegman JM, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362-371. doi: 10.4049/ jimmunol.177. 1. 362. Go to original source...
- Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J. 2020;16(14): 1816-21. Go to original source... Go to PubMed...